To assess treatments for MASLD and its severe form, MASH, GemPharmatech developed the B6-Alms1-del mouse model. Previous studies have shown that this model spontaneously develops metabolic syndrome (including obesity, hyperglycemia, hyperinsulinemia, and dyslipidemia) and MASH, with these conditions mitigated by treatment with the GLP-1R agonist semaglutide. In this study, we evaluated two additional promising anti-MASH agents, Tirzepatide (a GLP-1R & GIPR dual agonist) and Efruxifermin (an FGF21 analog, also known as AKR001), using the B6-Alms1-del MASH animal model.